Jennison Associates
SAGE

Jennison Associates’s Sage Therapeutics SAGE Stock Holding History

Jennison Associates’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-582,120
Closed -$33.1M – 718
2021
Q2 		$33.1M Buy
582,120
+22,594
+4% +$1.6M 0.02% 295
2021
Q1 		$41.9M Sell
559,526
-4,442
-0.8% -$364K 0.03% 244
2020
Q4 		$48.8M Buy
563,968
+125,603
+29% +$9.26M 0.03% 207
2020
Q3 		$26.8M Buy
438,365
+220,127
+101% +$11.2M 0.02% 274
2020
Q2 		$9.07M Buy
218,238
+571
+0.3% +$20.7K 0.01% 384
2020
Q1 		$6.25M Sell
217,667
-213,542
-50% -$12.4M 0.01% 375
2019
Q4 		$31.1M Sell
431,209
-2,412,480
-85% -$297M 0.03% 251
2019
Q3 		$399M Sell
2,843,689
-110,224
-4% -$18.4M 0.42% 48
2019
Q2 		$541M Buy
2,953,913
+598,299
+25% +$102M 0.54% 44
2019
Q1 		$375M Buy
2,355,614
+1,509,950
+179% +$219M 0.37% 49
2018
Q4 		$81M Buy
845,664
+35,440
+4% +$4.06M 0.09% 130
2018
Q3 		$114M Buy
810,224
+4,863
+0.6% +$751K 0.11% 122
2018
Q2 		$126M Buy
805,361
+14,338
+2% +$2.25M 0.12% 116
2018
Q1 		$127M Buy
791,023
+112,316
+17% +$19.1M 0.13% 114
2017
Q4 		$112M Sell
678,707
-195,043
-22% -$18.9M 0.11% 134
2017
Q3 		$54.4M Sell
873,750
-215,778
-20% -$16.9M 0.06% 258
2017
Q2 		$86.8M Buy
1,089,528
+4,806
+0.4% +$347K 0.09% 175
2017
Q1 		$77.1M Buy
1,084,722
+256,247
+31% +$15M 0.08% 204
2016
Q4 		$42.3M Buy
828,475
+2,731
+0.3% +$129K 0.05% 292
2016
Q3 		$38M Buy
825,744
+392,333
+91% +$16M 0.04% 317
2016
Q2 		$13.1M Buy
433,411
+1,866
+0.4% +$62.2K 0.01% 447
2016
Q1 		$13.8M Buy
431,545
+176,400
+69% +$6.21M 0.01% 438
2015
Q4 		$14.9M Buy
+255,145
New +$12.6M 0.01% 450

Other funds holding SAGE

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Jennison Associates's SAGE Position: Q3 2021 in Review

Jennison Associates sold out of Sage Therapeutics (SAGE) in Q3 2021, closing a stake of 582,120 shares — an estimated $33.1M sold.

Jennison Associates first reported a position in SAGE in Q4 2015 and held it in 23 quarters. The position peaked at $541M in Q2 2019. 225 funds tracked by Wall St. Rank hold SAGE as of Q3 2021.

  • Jennison Associates reported no remaining Sage Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Jennison Associates sold 582,120 Sage Therapeutics shares in Q3 2021, an estimated $33.1M.
  • Jennison Associates first reported a position in Sage Therapeutics in Q4 2015 and held it in 23 quarters.
  • Jennison Associates's Sage Therapeutics position peaked at $541M in Q2 2019.
  • 225 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2021.

Based on Jennison Associates's 13F filing for Q3 2021, filed 9 Nov 2021.